Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One-Size-Fits-No-One: study tailors blood thinner length to prevent repeat clots

NCT ID NCT06087952

Disease control Sponsor: Leiden University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using a person's individual risk of another blood clot or major bleeding can help doctors decide how long they should take blood thinners after a first clot. About 600 adults who had a first deep vein thrombosis or pulmonary embolism will fill out a questionnaire and provide a cheek swab to estimate their risks. Based on this, some will be randomly assigned to different treatment durations to see which approach works best.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 608 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2021

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Provision of informed consent prior to any study specific procedures. 2. Be diagnosed with a first confirmed symptomatic deep vein thrombosis (including distal vein thrombosis, in Dutch: 'kuitvenetrombose') or pulmonary embolism with an indication for treatment with anticoagulant therapy for at least 3 months as prescribed by their treating physician. 3. Be aged 18 years or above. Exclusion Criteria: 1. Patients with active cancer (i.e. cancer diagnosis within six months before VTE (excluding basal-cell or squamous-cell carcinoma of the skin), recently recurrent or progressive cancer or any cancer that required anti-cancer treatment within six months before the venous thromboembolism was diagnosed) or antiphospholipid syndrome 2. Patients who need to continue anticoagulant treatment for another indication (e.g. atrial fibrillation). 3. Patients with a strong indication for long-term antiplatelet therapy despite oral anticoagulation (e.g. those with recent STEMI) 4. Patients with COVID-19 associated VTE (hospital admission because of COVID-19 \<3 months before the VTE) or vaccine-induced immune thrombotic thrombocytopenia (VITT) 5. Patients in whom the risk of bleeding is deemed extremely high by the treating physician, necessitating discontinuation of anticoagulant treatment for the first VTE after the initial 3 months or even during the initial 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Deep vein thrombosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary embolism venous thromboembolism Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Deep vein thrombosis Pulmonary embolism Venous thromboembolism Venous thromboses

Contacts and locations

Locations

  • Admiraal de Ruyter Ziekenhuis

    Goes, Netherlands

  • Amphia Ziekenhuis

    Breda, Netherlands

  • Amsterdam Medical Center, location AMC

    Amsterdam, Netherlands

  • Catharina Ziekenhuis

    Eindhoven, Netherlands

  • Deventer Ziekenhuis

    Deventer, Netherlands

  • Diakonessenhuis

    Utrecht, Netherlands

  • Groene Hart Ziekenhuis

    Gouda, Netherlands

  • Haaglanden Medisch Centrum

    The Hague, Netherlands

  • HagaZiekenhuis

    The Hague, Netherlands

  • Ikazia Ziekenhuis

    Rotterdam, Netherlands

  • Isala Klinieken

    Zwolle, Netherlands

  • Leiden University Medical Center

    Leiden, South Holland, 2333 ZA, Netherlands

  • Martini Ziekenhuis

    Groningen, Netherlands

  • Nij Smellinghe Ziekenhuis

    Drachten, Netherlands

  • Radboud University Medical Center

    Nijmegen, Netherlands

  • Rode Kruis Ziekenhuis

    Beverwijk, Netherlands

  • University Medical Center Groningen

    Groningen, Netherlands

  • Wilhelmina Ziekenhuis

    Assen, Netherlands

  • Ziekenhuis Gelderse Vallei

    Ede, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.